CF33-hNIS

AXP000099.1 · Oncolytic virus

Platform
chimeric orthopoxvirus (CF33)
Originator
City of Hope (Yuman Fong)
Sponsor
Imugene

Names

NameTypeSource
CF33-hNISpreferred name, codecurator, ctgov
VAXINIAbrandctgov
HOV2codectgov

Virus

Role
Oncolytic
Family
Poxviridae
Virus
chimeric orthopoxvirus (CF33)
Strain
CF33
Replication
conditionally replicating
Modifications
thymidine kinase locus replaced by the hNIS expression cassette
Transgenes
SLC5A5 (hNIS)
Route
intratumoral, intravenous
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (2)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05346484A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid TumorsTerminatedPhase 12022-05-172026-01-1266Advanced Solid Tumor; Bile Duct Cancer; Cholangiocarcinoma; Metastatic Cancer; Solid Carcinoma; Solid Tumor; Solid Tumor, Adult
NCT05081492CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast CancerActive not recruitingPhase 12021-10-182027-03-019Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 40933893hNIS-based imaging to monitor treatment with the novel oncolytic virus CF33-hNIS-antiPDL1 in humans with advanced triple negative breast cancer.Frontiers in oncology2025cited by trial NCT05081492
PMID 38028143CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study.Therapeutic advances in medical oncology2023cited by trial NCT05081492

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41104781Oncolytic Properties of the Chimeric Poxvirus HOV-2 in Cholangiocarcinoma Models.Journal of the American College of Surgeons2026name in title: HOV2
PMID 41922086Intraperitoneal CF33-hNIS combined with PD-L1 blockade eradicates gastric cancer peritoneal metastases and prevents recurrence via durable T cell memory.Journal for immunotherapy of cancer2026name in title: CF33-hNIS
PMID 40782434CF33-hNIS-antiPDL1 enhances immunogenicity and anti-tumor efficacy in an orthotopic syngeneic pancreatic cancer mouse model.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2025name in title: CF33-hNIS
PMID 37019471Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases.Journal for immunotherapy of cancer2023name in abstract: CF33-hNIS
PMID 37196156An Oncolytic Poxvirus Encoding hNIS, Shows Antitumor Efficacy and Allows Tumor Imaging in a Liver Cancer Model.Molecular cancer therapeutics2023name in abstract: CF33-hNIS
PMID 37318642Current perspectives on Vaxinia virus: an immuno-oncolytic vector in cancer therapy.Medical oncology (Northwood, London, England)2023name in title: VAXINIA
PMID 37762490Anti-Tumor Immunogenicity of the Oncolytic Virus CF33-hNIS-antiPDL1 against Ex Vivo Peritoneal Cells from Gastric Cancer Patients.International journal of molecular sciences2023name in title: CF33-hNIS
PMID 34108669CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy.Cancer gene therapy2022name in title: CF33-hNIS
PMID 35024377A comprehensive preclinical study supporting clinical trial of oncolytic chimeric poxvirus CF33-hNIS-anti-PD-L1 to treat breast cancer.Molecular therapy. Methods & clinical development2022name in title: CF33-hNIS
PMID 35118191PET imaging and treatment of pancreatic cancer peritoneal carcinomatosis after subcutaneous intratumoral administration of a novel oncolytic virus, CF33-hNIS-antiPDL1.Molecular therapy oncolytics2022name in title: CF33-hNIS
PMID 32032721Novel Chimeric Immuno-Oncolytic Virus CF33-hNIS-antiPDL1 for the Treatment of Pancreatic Cancer.Journal of the American College of Surgeons2020name in title: CF33-hNIS
PMID 32158622Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model.Oncoimmunology2020name in title: CF33-hNIS
PMID 31061881A Novel Chimeric Poxvirus Encoding hNIS Is Tumor-Tropic, Imageable, and Synergistic with Radioiodine to Sustain Colon Cancer Regression.Molecular therapy oncolytics2019name in abstract: CF33-hNIS
PMID 8181900Noradrenergic modulation of lymphohematopoiesis.International journal of immunopharmacology1994name in abstract: VAXINIA

Notes

Trade-named VAXINIA. CF33 is a chimera assembled by co-infection with nine orthopoxviruses, so no single parent NCBI taxon is given. Phase 1 MAST study (NCT05346484) dosed patients intratumorally and intravenously; terminated January 2026.

How to cite

CF33-hNIS (AXP000099.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000099.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.